NDRI July webinar: The impact of opioid agonist treatment (OAT)
Wednesday July 13, 11am–noon WST, 1–2pm EST
Opioid agonist treatment (OAT) engagement protects against overdose mortality, blood borne virus transmission, and other harms that implicate people with opioid use disorder. These studies aimed to determine the impact of OAT on hospitalisations for injecting-related diseases and self-harm, and on suicide mortality, using large linked administrative health datasets in New South Wales.
Dr Samantha Colledge-Frisby is a Research Fellow at the National Drug Research Institute Melbourne, and an honorary Research Fellow at the Burnet Institute and the National Drug and Alcohol Research Centre. She completed her PhD in early 2022, and her thesis expanded our understanding of harms that contribute to morbidity among people who inject drugs. Her research interests span injecting-related bacterial infections, overdose, self-harm, and mental health disorders within this population and other populations of people who have substance use disorders.
Click here to view the recording
Posted on: 13 Jun 2022